Sinopharm Coronavirus Vaccine Was Approved for Market Entry in China
OREANDA-NEWS. According to China Central Television, the State Food and Drug Administration has approved the market launch of Sinopharm's inactivated coronavirus vaccine. Sinopharm representatives say that their new inactivated vaccine after vaccination has demonstrated a good level of safety, after two injections, the vaccinated have developed high titer antibodies, the protective efficacy of the COVID-19 vaccine was 79.34%.
The inactivated COVID-19 vaccine developed by China National Biotech Group of Sinopharm Corp. has already received market approval with additional conditions, the report said. It is noted that the new apparatus complies with the requirements of the State Food and Drug Administration and the World Health Organization.
The report also indicates that further monitoring of the duration and effectiveness of the vaccine is still required.
China was the first to develop a vaccine against COVID and was also among the first to begin clinical trials, but at the start of the third phase of trials, Chinese experts were faced with the fact that the country itself did not actually have a virus and, accordingly, a suitable environment for conducting all the necessary tests. As a result, the third phase of clinical tests had to be carried out mainly in other countries.
Earlier, the chairman of the board of directors of Sinopharm, Liu Jingzhen, reported that two inactivated vaccines against coronavirus infection, developed by the company, are already in the third phase of clinical trials in 10 countries, including the UAE, Bahrain, Egypt, Jordan, Peru, Argentina. More than 60 thousand people took part in tests abroad, while 40 thousand of them had already received two injections, 14 days after the second injection, blood samples were taken from them for analysis - and the results were "extremely good." The expert also clarified that about one million people have already been vaccinated with an inactivated COVID-19 vaccine developed by the company.